Ido1 and Ido2 deficiencies attenuate kainic acid-induced ictogenesis

Insults to the brain in the form of injury, infection and exposure to seizurogenic chemicals can induce seizures (ictogenesis). Seizure episodes during any of these events is one of the biggest risk factors for the development of treatment-resistant epilepsy, making the acute ictogenic period a critical time for intervention. Indoleamine-2,3-dioxygenases (Ido1 & Ido2) modulate systemic and central neuroprotective and inflammatory responses through both enzymatic and non-enzymatic mechanisms. We have previously found that Ido1<sup>-/-</sup> (knockout) mice have increased seizure incidence following viral encephalitis suggesting a protective role of Ido1 during this inflammatory model of ictogenesis. Here, we assessed ictogenesis with Ido1<sup>-/-</sup> and Ido2<sup>-/-</sup> mice using intraperitoneal injections of the chemoconvulsant kainic acid (KA). We found that Ido1<sup>-/-</sup> and Ido2<sup>-/-</sup> mice have reduced seizure incidence after systemic KA treatment compared to WT controls. However, neither Ido1 nor Ido2 expression was induced by KA and indices of inflammation (hippocampal cytokine expression) did not vary across genotypes. Nevertheless, Ido2<sup>-/-</sup> mice were also protected from the KA-induced hyperlocomotion observed with WT mice. Because Ido1 and Ido2 are expressed by multiple cell types within the brain,we evaluated KA-induced ictogenesis using mice with cell-type-specific Ido1 and Ido2 deficiencies. Ido1 or Ido2 deficiency in neurons, astrocytes and myeloid-derived cells all increase ictogenesis, whileonly a deficiency of microglial Ido2 (not Ido1) had this enhancing effect. Thus, the results of cell-type-specific Ido1 and Ido2 deficiencies differed from that of the global knockout, suggesting that neurons, astrocytes, microglia and macrophages utilize Ido1 and Ido2 to protect against ictogenesis, whereas Ido1 or Ido2 within other cells of the brain or the periphery drive ictogenesis. Thus, peripheral Ido1 and Ido2 may provide a novel target for anti-seizure drug discovery, but input from individual cell types should be carefully considered.

Authors

Institutions

Publication Details

Journal
Brain Research
Published
2026-02-14
DOI
https://doi.org/10.1016/j.brainres.2026.150204
Primary Topic
Tryptophan and brain disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ido1 and Ido2 deficiencies attenuate kainic acid-induced ictogenesis

Robert H. McCusker, Myrna Hurtado, Emily Y. Chen, Zoë A. MacDowell Kaswan
Brain Research
Tryptophan and brain disorders
article

Ido1 and Ido2 deficiencies attenuate kainic acid-induced ictogenesis

Robert H. McCusker, Myrna Hurtado, Emily Y. Chen, Zoë A. MacDowell Kaswan
article en

Abstract

Insults to the brain in the form of injury, infection and exposure to seizurogenic chemicals can induce seizures (ictogenesis). Seizure episodes during any of these events is one of the biggest risk factors for the development of treatment-resistant epilepsy, making the acute ictogenic period a critical time for intervention. Indoleamine-2,3-dioxygenases (Ido1 & Ido2) modulate systemic and central neuroprotective and inflammatory responses through both enzymatic and non-enzymatic mechanisms. We have previously found that Ido1<sup>-/-</sup> (knockout) mice have increased seizure incidence following viral encephalitis suggesting a protective role of Ido1 during this inflammatory model of ictogenesis. Here, we assessed ictogenesis with Ido1<sup>-/-</sup> and Ido2<sup>-/-</sup> mice using intraperitoneal injections of the chemoconvulsant kainic acid (KA). We found that Ido1<sup>-/-</sup> and Ido2<sup>-/-</sup> mice have reduced seizure incidence after systemic KA treatment compared to WT controls. However, neither Ido1 nor Ido2 expression was induced by KA and indices of inflammation (hippocampal cytokine expression) did not vary across genotypes. Nevertheless, Ido2<sup>-/-</sup> mice were also protected from the KA-induced hyperlocomotion observed with WT mice. Because Ido1 and Ido2 are expressed by multiple cell types within the brain,we evaluated KA-induced ictogenesis using mice with cell-type-specific Ido1 and Ido2 deficiencies. Ido1 or Ido2 deficiency in neurons, astrocytes and myeloid-derived cells all increase ictogenesis, whileonly a deficiency of microglial Ido2 (not Ido1) had this enhancing effect. Thus, the results of cell-type-specific Ido1 and Ido2 deficiencies differed from that of the global knockout, suggesting that neurons, astrocytes, microglia and macrophages utilize Ido1 and Ido2 to protect against ictogenesis, whereas Ido1 or Ido2 within other cells of the brain or the periphery drive ictogenesis. Thus, peripheral Ido1 and Ido2 may provide a novel target for anti-seizure drug discovery, but input from individual cell types should be carefully considered.

Brain ResearchVol. 1877-1878
University of Illinois Urbana-Champaign (US), Urbana University (US)
Good health and well-being
Openalex Percentile: Top 58%
Tryptophan and brain disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.